FDA Extends Deramiocel Review to November 22 After Major Amendment
FDA extended the PDUFA target action date for Capricor’s deramiocel BLA from August 22 to November 22, 2026, after the company submitted a major amendment. The amendment adds 24-month open-label extension data from Phase…
